• Users Online: 152
  • Print this page
  • Email this page


 
 
Table of Contents
CASE REPORT
Year : 2021  |  Volume : 9  |  Issue : 4  |  Page : 259-263

A case report of pleural effusion in a COVID-19 patient with multiple comorbidities


Department of Medicine, Bowring and Lady Curzon Medical College and Research Institute, Bengaluru, Karnataka, India

Date of Submission23-Oct-2020
Date of Decision28-Nov-2020
Date of Acceptance13-Mar-2021
Date of Web Publication20-Oct-2021

Correspondence Address:
Dr. C N Mohan
#312/A 6th Main, 4th Block, 3rd Stage, Basaveshwara Nagar, Bengaluru - 560 079, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ajim.ajim_82_20

Rights and Permissions
  Abstract 


We report a case of coronavirus disease 2019 (COVID-19) infection in a patient with multiple comorbidities diabetes, hypertension, ischemic heart disease, and chronic liver disease. Although pleural effusion is rarely seen in COVID-19 infection, the presence of which should be interpreted carefully. In this case report, our patient presented with complaints of fever, cough, and dyspnea, and focused clinical examination revealed fullness in the left hemithorax compared to right; reduced chest movements in the left hemithorax and trachea deviated to the right; dullness in the left hemithorax and right infrascapular, infra-axillary, and mammary area; and absent breath sounds in areas where dullness was noted. A chest X-ray done revealed left massive pleural effusion with right mild pleural effusion and pleural fluid analysis on both sides revealed transudate picture; this was also similar to the ascitic fluid analysis that was done in this patient; at this point of time, a computed tomography of the thorax was done to rule out other causes of pleural effusion. Meanwhile, other laboratory investigations revealed evidence of liver cell failure showing hyperbilirubinemia, hypoalbuminemia, and deranged prothrombin time and international normalized ratio (INR) and imaging evidence of cirrhotic liver; the patient was treated accordingly. Therapeutic pleural tapping was done after INR normalized; the patient improved symptomatically. Pleural effusion although is a rare manifestation of COVID-19, the etiologies are varied, it is important for us to consider other possible comorbidities associated in a patient who is hospitalized for acute illness, in this case, the patient had multiple comorbidities such as diabetes, hypertension, ischemic heart disease, and chronic liver disease, and the cause for pleural effusion is attributed to decompensated chronic liver disease and ischemic heart disease. In this case, the acute infection has resulted in the decompensation of his preexisting chronic disease.

Keywords: Chest X-ray, coronavirus disease 2019, pleural effusion


How to cite this article:
Mahendra M, Siddesh N, Mohan C N, Narayanaswamy M. A case report of pleural effusion in a COVID-19 patient with multiple comorbidities. APIK J Int Med 2021;9:259-63

How to cite this URL:
Mahendra M, Siddesh N, Mohan C N, Narayanaswamy M. A case report of pleural effusion in a COVID-19 patient with multiple comorbidities. APIK J Int Med [serial online] 2021 [cited 2021 Nov 29];9:259-63. Available from: https://www.ajim.in/text.asp?2021/9/4/259/328685




  Introduction Top


In December 2019, novel coronavirus disease 2019 (COVID-19) exploded out in Wuhan, China. The pathogen, severe acute respiratory syndrome coronavirus 2, is a novel β-coronavirus and transmitted mainly through droplets and close contact. It is highly contagious and can spread quickly such that the entire human population is susceptible. Patients often presented with respiratory symptoms and fever 5–6 days after being infected with the virus (latency period ranging 1–14 days). Most cases develop into mild infection that subsides on its own, but severe cases often lead to death, especially in elders and patients with associated comorbidities.[1] The clinical expressions of COVID-19 range from asymptomatic course to mild-to-severe form, characterized by dyspnea and/or hypoxemia that can quickly progress to septic shock, refractory metabolic acidosis, coagulation disorders, need for intensive care, and death in 4.3%–15% of patients.[2] Early disease progression can be rapid.[3] The severe clinical form is characterized by abnormal laboratory findings, such as hyperferritinemia, leukopenia, alterations of liver function tests (LFTs), and high levels of cytokines (i.e., interleukin (IL)-6, IL-1B, IL-1RA, IL-2, IL-10, and tumor necrosis factor α)[3],[4] and chemokines such as inducible protein-10 and monocyte chemoattractant protein-1.[5],[6] Liver injury in patients with coronavirus infections is often transient and can be directly caused by the viral infection of liver cells.[7] Several evidence suggest that the virus may induce a proinflammatory state related to the overactivation of effector T-cells with associated massive production of proinflammatory cytokines that may play a key role in the development of the lung disease and damage, which in turn leads to acute lung injury.[8],[9],[10] In the absence of a specific treatment or vaccine for COVID-19, early diagnosis and the subsequent isolation of infected patients are essential for disease control.

Chest radiographs may be normal in early/mild disease. In those COVID-19 cases requiring hospitalization, 69% had an abnormal chest radiograph at the initial time of admission, and 80% had radiographic abnormalities sometime during hospitalization.[11] Findings are most extensive about 10–12 days after onset of symptoms.[11] The most frequent findings are airspace opacities, whether described as consolidation or, less commonly, ground-glass opacity (GGO).[11],[12] The distribution is most often bilateral, peripheral, and lower zone predominant.[11],[12] In contrast to parenchymal abnormalities, pleural effusion is rare (3%).[11]

Although cardiac manifestations of COVID-19 are well recognized, there is no published evidence of cardiac disease on chest radiographs.[13] Pleural effusion is seldom seen in COVID-19;[14],[15] it is seen that pleural effusion tends to occur with recurrent pneumonia or late in the course of COVID-19 pneumonia (beyond 3rd week). The incidence of pleural effusion is higher in other viral pneumonia compared to COVID-19 pneumonia (39% vs. 4%)[16] and also that pleural effusion is common in patients who are critically ill, 8% in mild symptoms, and 28% in critically ill.[17]

We report a case of COVID-19 infection in a patient who presented with left massive pleural effusion on chest radiography, which was the early sign and the presenting manifestation, and on careful history and investigation, it was found that this patient had multiple comorbidities. The causes for pleural effusion are often overlooked, as in this case; it appeared that COVID-19 pneumonia was the cause for the pleural effusion, but on careful investigation, the reason for effusion was due to decompensation of underlying chronic disease caused by acute infection. Thereby, a careful history and focused clinical examination are necessary in every case in conjunction with necessary investigations to make an accurate diagnosis and better treatment outcome.


  Case Report Top


A 50-year-old male presented with a history of hypertension, type 2 diabetes mellitus, and dyslipidemia for 12 years on regular medications. He was also a known chronic alcoholic for 10 years with last drink 7 months back. The patient also gave a history of ischemic heart disease status postpercutaneous transluminal coronary angioplasty (PTCA) 5 years back on cardiac medications. The patient is a street vendor by occupation and had completed his education up to the 8th grade. The patient satisfied cut-annoyed-guilty-eye (CAGE) criteria for alcohol dependence and had not undergone any deaddiction treatment in the past. This patient was referred to us from other hospital for further management. The patient presented with a history of shortness of breath, fever, and cough with expectoration for 2 days. In the current pandemic situation, the patient was suspected to have COVID-19 infection for which rapid antigen test (RAT) was positive. Upon arrival in the emergency room, the patient was found to be tachypneic and not maintaining saturation on room air (SPO2 96% with 4 l/min on face mask) and the rest of the vital parameters were within normal limits.

On general physical examination, the patient had pallor and icterus. On systemic examination, the patient was found to have abdominal distension with free fluid. There was no hepatosplenomegaly on per abdomen examination. The patient did not have asterixis and was not in hepatic encephalopathy.

The patient was diagnosed to have severe acute respiratory illness COVID-19 positive (RAT positive) type 2 diabetes, hypertension, and ischemic heart disease status post-PTCA. The patient was started on supplemental oxygen via face mask 4 l/min, IV antibiotics, IV steroids, and other supportive measures according to the national guidelines for COVID-19.

Baseline investigation revealed hemoglobin of 6.8 g/dl, total bilirubin of 2.8 mg/dl, direct bilirubin of 1.3 mg/dl, albumin of 2.3 g/dl, aspartate aminotransferase of 93 U/l, alanine aminotransferase of 45 U/l, prothrombin time (PT) of 16.6, international normalized ratio (INR) of 1.3, and D-dimer of 1050 ng/ml. The patient was considered for initiation of remdesivir therapy, but in view of deranged LFTs, medical gastroenterology opinion was sought, and as per advice, remdesivir was started and daily LFT monitoring was done [Table 1]. Initial chest radiograph revealed left massive effusion with underlying lung collapse with the trachea pushed to the right side [Figure 1].
Table 1: Relevant investigations

Click here to view
Figure 1: Chest X-ray – On admission (before tapping)

Click here to view


Chest radiograph was done on admission [Figure 1] and after left-sided thoracentesis revealed partial resolution with respect to degree of effusion [Figure 2]. Ultrasonography (USG) of the abdomen revealed cirrhotic liver disease with reduced portal velocity and gross ascites. The patient was planned for computed tomography (CT) of the thorax; as the patient was not maintaining saturation, it was deferred. USG thorax showed left pleural effusion with underlying lung collapse. Abdominal therapeutic paracentesis done with paracentesis fluid was sent for analysis and was consistent with transudative picture. The patient was given 1 unit of packed red blood cell transfusion. The patient was given fusion 1 unit of albumin infusion in view of hypoalbuminemia. The patient improved symptomatically and CT done later showed ground-glass opacities and consolidation in bilateral lung fields with CT severity score of 4/25 (mild) with bilateral pleural effusion (left > right) with features suggestive of cirrhotic liver disease with gross ascites [Figure 3]. During the course in the hospital, the patient often developed hypoglycemia, for which he was treated accordingly. The patient had a hospital stay for 2 weeks and repeated swab for COVID-19 done before discharge was negative. The patient had improved symptomatically and was discharged and was advised accordingly regarding follow-up. A X-ray was done at the time of discharge (day 14) [Figure 4].
Figure 2: Chest X-ray, day 3, after tapping

Click here to view
Figure 3: Computed tomography thorax showing ground-glass opacities and consolidation in bilateral lung fields with computed tomography severity score of 4/25 (mild) with bilateral pleural effusion (left > right)

Click here to view
Figure 4: Chest X-ray – At the time of discharge day 14

Click here to view



  Discussion Top


The reported prevalence of pleural effusion in COVID-19 pneumonia has been variable in recently published investigations.[18] According to the study by Shi et al.,[19] the prevalence of pleural effusion varies depending on the stage of the disease, with a reported prevalence of 13% in the 3rd week after onset of symptoms. Pleural effusion may also be predictive of a worse prognosis and can indicate bacterial superinfection in COVID-19.[18]

With the worldwide spread of COVID-19, uncommon presentations are still being reported. In our case, all clinical characteristics including signs and symptoms, laboratory investigations, and the results of radiography of the chest suggested COVID-19. The diagnosis was confirmed on COVID-19 RAT. However, pleural effusion, which was diagnosed on radiograph of the chest, is rare in the early phase of the disease.[19] It usually occurs with recurrent pneumonia or after the 3rd week of COVID-19 pneumonia. At this stage, patients are severely sick compared with other patients. A study reported that the percentage of pleural effusion is 8% in patients with mild symptoms compared with 28% in patients critically ill with COVID-19.[17]

Our patient presented with moderate symptoms at an early stage and his medical examination and radiography revealed pleural effusion. Although most patients have mild symptoms and a good prognosis, COVID-19 can develop into severe illness including pneumonia, pulmonary edema, acute respiratory distress syndrome, multiple organ failure, coagulation abnormalities, and even death.

The primary findings of COVID-19 on chest radiograph and CT are those of atypical pneumonia[13],[20] or organizing pneumonia.[21],[22] However, imaging has limited sensitivity for COVID-19, as up to 18% demonstrate normal chest radiographs or CT when mild or early in the disease course, but this decreases to 3% in severe disease.[12],[23] Bilateral and/or multilobar involvement is common.[24],[25]

Chest radiographs may be normal in early/mild disease. In those COVID-19 cases requiring hospitalization, 69% had an abnormal chest radiograph at the initial time of admission, and 80% had radiographic abnormalities sometime during hospitalization.[11] Findings are most extensive about 10–12 days after onset of symptoms.[11] The most frequent findings are airspace opacities, whether described as consolidation or, less commonly, GGO.[11],[12] The distribution is most often bilateral, peripheral, and lower zone predominant.[11],[12] In contrast to parenchymal abnormalities, pleural effusion is rare (3%).[11]

In view of the existing comorbidities, the clinical picture was complicated and contributed for difficulties of diagnosis. Hypoalbuminemia, deranged PT/INR, anemia, and the presence of associated comorbidities are associated with poor prognosis and also pose a challenge in treating these patients; treatment under such circumstances will be based on risk and benefit ratio.


  Conclusion Top


The accurate comment on the prevalence and etiology of pleural effusion in COVID-19 infection should be based on the presence or absence of underlying medical conditions, study setting, disease stage, and concurrent superimposed bacterial pneumonia. Hence, the presence of pleural effusion cannot always be solely attributed to COVID-19 pneumonia.

The coronavirus can have a variety of presentations with unusual radiological findings. Keen clinical judgment with appropriate investigations is mandatory for prompt diagnosis and treatment. Due to the current pandemic situation and the patient was COVID-19 positive and the patient had disproportionate respiratory distress and patient with multiple comorbidities, there was confusion in arriving at diagnosis. However, the superadded COVID-19 infection with preexisting multiple comorbidities in this patient worsened the prognosis and added on to the morbidity. Careful judgment and timely management are approximately necessary and sequential investigation (radiography). High clinical suspicion and ruling out the etiological causes are essential part of the management in multiple comorbidities with COVID-19.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Report of the WHO China Joint Mission on Coronavirus Disease 2019 (COVID 19); 2020. Available from: https://www.who.int/docs/default source/coronaviruse/ who china joint mission on covid 19 final report.pdf. [Last accessed on 2020 Oct 22].  Back to cited text no. 1
    
2.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.  Back to cited text no. 2
    
3.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.  Back to cited text no. 3
    
4.
Okabayashi T, Kariwa H, Yokota SI, Iki S, Indoh T, Yokosawa N, et al. Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. J Med Virol 2006;78:417-24.  Back to cited text no. 4
    
5.
Lo AW, Tang NL, To KF. How the SARS coronavirus causes disease: Host or organism? J Pathol 2006;208:142-51.  Back to cited text no. 5
    
6.
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017;39:529-39.  Back to cited text no. 6
    
7.
Zhang C, Shi L, Wang FS. Liver injury in COVID-19: Management and challenges. Lancet Gastroenterol Hepatol 2020;5:428-30.  Back to cited text no. 7
    
8.
Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 2016;19:181-93.  Back to cited text no. 8
    
9.
Dholaria BR, Bachmeier CA, Locke F. Mechanisms and management of chimeric antigen receptor T-Cell therapy-related toxicities. BioDrugs 2019;33:45-60.  Back to cited text no. 9
    
10.
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188-95.  Back to cited text no. 10
    
11.
Wong HY, Lam HY, Fong AH, Leung ST, Chin TW, Lo CS, et al. Frequency and distribution of chest radiographic findings in patients positive for COVID-19. Radiology 2020;296:E72-8.  Back to cited text no. 11
    
12.
Rodrigues JC, Hare SS, Edey A, Devaraj A, Jacob J, Johnstone A, et al. An update on COVID-19 for the radiologist – A British Society of Thoracic Imaging statement. Clin Radiol 2020;75:323-5.  Back to cited text no. 12
    
13.
Cleverley J, Piper J, Jones MM. The role of chest radiography in confirming covid 19 pneumonia. BMJ 2020;370:M2426.  Back to cited text no. 13
    
14.
Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R, et al. Diagnosis treatment, and prevention of 2019 novel coronavirus infection in children: Experts' consensus statement. World J Pediatr 2020;16:223-31.  Back to cited text no. 14
    
15.
National Health Commission of People's Republic of China. Diagnosis and treatment for the novel coronavirus pneumonia (trial version 5). Available from: http://www.nhc.gov.cn/xcs/ zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440/ files/7260301a393845fc87fcf6dd52965ecb.pdfExternal Link. [Last cited on 2020 Feb 08].  Back to cited text no. 15
    
16.
Lal A, Mishra AK, Sahu KK. CT chest findings in coronavirus disease 19 (COVID 19). J Formos Med Assoc 2020;119:1000 1.  Back to cited text no. 16
    
17.
Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early clinical and CT manifestations of coronavirus disease 2019 (COVID 19) pneumonia. AJR Am J Roentgenol 2020;215:338-43.  Back to cited text no. 17
    
18.
Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID 19): A pictorial review. Eur Radiol 2020;30:4381-9.  Back to cited text no. 18
    
19.
Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020;20:425-34.  Back to cited text no. 19
    
20.
Kooraki S, Hosseiny M, Myers L, Gholamrezanezhad A. Coronavirus (COVID 19) outbreak: What the department of radiology should know. J Am Coll Radiol 2020;17:447-51.  Back to cited text no. 20
    
21.
Kanne JP, Little BP, Chung JH, Elicker BM, Ketai LH. Essentials for radiologists on COVID 19: An update–radiology scientific expert panel. Radiology 2020;296:E113-4.  Back to cited text no. 21
    
22.
Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. Journal of travel medicine. 2020 Mar 13.  Back to cited text no. 22
    
23.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.  Back to cited text no. 23
    
24.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.  Back to cited text no. 24
    
25.
Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 2020;295:202-7.  Back to cited text no. 25
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]
 
 
    Tables

  [Table 1]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
Abstract
Introduction
Case Report
Discussion
Conclusion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed108    
    Printed0    
    Emailed0    
    PDF Downloaded9    
    Comments [Add]    

Recommend this journal